Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

MHRA approves Chiesi's Clenil Modulite (beclometasone dipropionate) with low-carbon propellant for asthma maintenance treatment
Small molecule, respiratory disease, inhaled corticosteroid, asthma, beclometasone dipropionate - Read more

Ashlins Pharmaceuticals, Lee's Pharmaceutical license interferon alpha-2b ex-China rights in $31M deal
Licensing deal, rare disease, small molecule, milestone payments, drug repurposing - Read more

Jupiter Neurosciences licenses MDMA asset ALA-002 from PharmAla Biotech, $3.3M upfront, $100M total deal
Licensing deal, neurological, small molecule, milestone payments, royalties - Read more

Royalty Pharma pays Neurimmune $425M for royalties on AstraZeneca-partnered ATTR drug cliramitug
Royalty financing, rare disease, cardiovascular, milestone payments, antibody - Read more

PolyPid, Azurity Pharmaceuticals partner on D-PLEX100 commercialization in U.S. and Canada, $330M+ deal
Commercialization agreement, infectious disease, small molecule, milestone payments, royalties - Read more

Tempest Therapeutics, Senlang Biotechnology collaborate on CD7-targeted in vivo CAR-T TPST-4003 development in China
Co-development, cell therapy, autoimmune, neurological, in vivo CAR-T, licensing deal - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

IMUNON's IMNN-001 (IMNN-001) shows positive Ph2 minimal residual disease data in frontline advanced ovarian cancer
Gene therapy, cancer, DNA immunotherapy, ovarian cancer, IL-12, tumor microenvironment - Read more

Novartis CEO dismisses Merck & Co.'s oral PCSK9 threat as Leqvio posts 59% Q2 sales growth
Small interfering RNA, cardiovascular, competitive, revenue impact - Read more

Crystalys Therapeutics raises $130M Series B to advance gout drug dotinurad through Phase 3
Gout, small molecule, clinical-stage, uric acid - Read more

Dimension raises $800M for third fund, investing in AI-driven biotech drug discovery
AI/ML platform, drug discovery, venture capital, platform-enabled - Read more

ZYUS Life Sciences Corporation closes CAD$150K ($107K) sixth tranche secured loan, non-opioid pain management
Clinical-stage, pain management, small molecule, non-opioid - Read more

Estrigenix Therapeutics raises $2M Series Seed, advancing ERβ platform for women's health and neurodegeneration
Women's health, neurological, small molecule, preclinical, platform technology - Read more

N-Zyme Biomedical closes $4.6M Series A to advance Phase 2 reflux disease programs
Reflux disease, small molecule, pepsin inhibitor, clinical-stage - Read more

Dyne Therapeutics prices upsized $375M public offering, advancing neuromuscular disease treatments
Clinical-stage, neuromuscular disease, rare disease, genetic medicine - Read more

Novartis to invest $95M in South Korea to expand radioligand therapy supply chain ecosystem
Radioligand therapy, oncology, strategic, major transaction, operational - Read more

Amgen agrees to $74M settlement over lawsuit alleging concealment of $10.7B IRS tax bill
Settlement, financial, operational, major transaction - Read more

Repligen to acquire BioLife Solutions for $1.5B, securing critical cryopreservation media for cell therapy market
Cell therapy, oncology, major transaction, strategic - Read more

61 biopharma companies file amicus brief backing FDA against Louisiana's "malicious" mifepristone access lawsuit
Small molecule, reproductive health, regulatory, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Celldex Therapeutics' (barzolvolimab) Ph2 fails to improve itch symptoms in prurigo nodularis patients
Antibody, autoimmune, monoclonal antibody, prurigo nodularis, KIT inhibitor, mast cell depletion - Read more

Trump proposes 100%-200% tariffs on imported generic drugs to reshore US production by 2028
Generic drugs, manufacturing, tariffs, pricing - Read more

FDA issues warning letter to Alembic Pharmaceuticals over patient informed consent failures in bioequivalence study
Generics, regulatory, operational, patient safety - Read more

Sanofi reprimanded by U.K. watchdog for misleading claims disparaging Pfizer's RSV vaccine
RSV vaccine, infectious disease, regulatory, competitive, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here